Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:25:02 EST Wed 18 Nov 2026
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR+ Search
SEDAR+ Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR+ Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login ID:
Password:
Save
Z:LLY
- ELI LILLY AND COMPANY -
https://www.lilly.com
10:25:02 EST
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
LLY
- Z
1.0
1,403.23
·
1,405.00
0.1
1,404.66
-10.77
-0.8
540.1
758,290
13,455
1,409.87
1,423.11
1,399.08
1,475.25 850.51
10:08:01
Nov 14
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Portfolio
Recent Trades - Last 10 of 13455
More trades...
Time ET
Ex
Price
Change
Volume
10:08:11
Z
1,404.7303
-10.8197
1
10:08:11
Z
1,404.1267
-11.3033
150
10:08:10
Z
1,401.4889
-14.0611
2
10:08:10
Z
1,404.11
-11.44
1
10:08:10
Z
1,404.6046
-10.9454
3
10:08:09
Z
1,403.23
-12.20
11
10:08:09
Z
1,404.98
-10.57
1
10:08:09
Z
1,404.105
-11.445
1
10:08:09
Z
1,404.105
-11.445
1
10:08:08
Z
1,404.105
-11.325
10
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2026-11-14 12:01
U:LLY
News Release
200
Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
2026-11-12 15:30
U:LLY
News Release
200
Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020
2026-11-11 09:45
U:LLY
News Release
200
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
2026-11-10 08:00
U:LLY
News Release
200
Life doesn't slow down, and Foundayo(TM) (orforglipron) patient Leanne Morgan is done waiting
2026-11-09 09:30
U:LLY
News Release
200
Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
2026-11-09 08:00
U:LLY
News Release
200
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
2026-11-06 06:47
U:LLY
News Release
200
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
2026-11-05 06:45
U:LLY
News Release
200
Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
2026-11-03 09:00
U:LLY
News Release
200
Peptide Therapies Are Changing the Future of Medicine - And the Market Could Reach $335 Billion
2026-10-29 09:00
U:LLY
News Release
200
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
2026-10-29 06:45
U:LLY
News Release
200
Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
2026-10-28 06:45
U:LLY
News Release
200
Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
2026-10-27 16:03
U:LLY
News Release
200
Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets
2026-10-26 11:19
U:LLY
News Release
200
Lilly declares fourth-quarter 2026 dividend
2026-10-25 03:30
U:LLY
News Release
200
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
2026-10-24 02:30
U:LLY
News Release
200
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRalpha-targeting ADC at ESMO 2026
2026-10-22 10:30
U:LLY
News Release
200
Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020
2026-10-19 04:40
U:LLY
News Release
200
Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis
2026-10-18 18:05
U:LLY
News Release
200
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress